Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2018100535) COMBINATION THERAPY
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2018/100535 International Application No.: PCT/IB2017/057549
Publication Date: 07.06.2018 International Filing Date: 30.11.2017
IPC:
A61K 39/00 (2006.01) ,A61K 31/506 (2006.01) ,A61P 35/00 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39
Medicinal preparations containing antigens or antibodies
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
495
having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
505
Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
506
not condensed and containing further heterocyclic rings
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35
Antineoplastic agents
Applicants:
GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED [GB/GB]; 980 Great West Road Brentford, Middlesex TW8 9GS, GB
Inventors:
BARBASH, Olena; US
KORENCHUK, Susan; US
SHERK, Christian; US
Priority Data:
62/428,76401.12.2016US
62/433,36313.12.2016US
Title (EN) COMBINATION THERAPY
(FR) POLYTHÉRAPIE
Abstract:
(EN) The present invention provides a combination of a Type II protein arginine methyltransferase (Type II PRMT) inhibitor and immuno-modulatory agent, wherein the immuno-modulatory agent is an anti-OX40 antibody or antigen binding fragment thereof. The present invention also provides methods for treating cancer in a human in need thereof, the methods comprising administering to the human a combination of a Type II PRMT inhibitor and an immuno-modulatory agent, wherein the immuno-modulatory agent is an anti-OX40 antibody or antigen binding fragment thereof, together with at least one of: a pharmaceutically acceptable carrier and a pharmaceutically acceptable diluent, thereby treating the cancer in the human. The present invention further provide a pharmaceutical composition comprising a therapeutically effective amount of a Type II PRMT inhibitor and a second pharmaceutical composition comprising a therapeutically effective amount of an immuno-modulatory agent, wherein the immuno-modulatory agent is an anti-OX40 antibody or antigen binding fragment thereof.
(FR) La présente invention concerne l'association d'un inhibiteur de la protéine arginine N-méthyltransférase de type II (PRMT de type II) et d'un agent immunomodulateur, l'agent immunomodulateur étant un anticorps anti-OX40 ou un fragment de liaison à l'antigène de ce dernier. La présente invention concerne également des méthodes de traitement du cancer chez le patient humain dont l'état nécessite de tels traitements, les méthodes comprenant l'administration au patient d'une association d'un inhibiteur de la PRM de type II et d'un agent immunomodulateur, l'agent immunomodulateur étant un anticorps anti-OX40 ou un fragment de liaison à l'antigène de ce dernier, avec au moins l'un des constituants suivants : un support pharmaceutiquement acceptable et un diluant pharmaceutiquement acceptable, l'invention permettant de cette façon de traiter le cancer chez l'humain. La présente invention concerne en outre une composition pharmaceutique comprenant une quantité thérapeutiquement efficace d'un inhibiteur de de la PRM de type II et une seconde composition pharmaceutique comprenant une quantité thérapeutiquement efficace d'un agent immunomodulateur, l'agent immunomodulateur étant un anticorps anti-OX40 ou un fragment de liaison à l'antigène de ce dernier.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)